Kidney Disease: Improving Global Outcomes (KDIGO) has announced that the latest draft of the Clinical Practice Guideline for Anemia in Chronic Kidney Disease (CKD) is now available for public comment. This guideline is designed to educate and provide comprehensive guidance to healthcare professionals on diagnosing, evaluating, and treating anemia in adults and children with CKD, […]
Read More
In the United States, 37 million people suffer from chronic kidney disease, with 10% of adults and 70% of children affected by genetic causes. Despite advancements in genetic testing and a growing understanding of the genetic factors contributing to kidney diseases, genetic testing in nephrology lags behind other medical specialties. To address this gap, we […]
Read MoreIn this edition of our Guidelines Monographs Series, we will be taking a look at AstraZeneca’s medication dapagliflozin, brand name Farxiga. Initially approved in 2014, Farxiga is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, provided to individuals with diabetes, heart disease, or kidney disease to improve their outcomes. This Guidelines+ Monograph will take a deeper dive […]
Read More